You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest US Food and Drug Administration Articles
Popular US Food and Drug Administration Articles
Highly Recommended US Food and Drug Administration Articles
Send a link to this page to your friends and colleagues.
NeuroMetrix, Inc., a Massachusetts-based medical device company, has filed a 510(k) form with the US Food and Drug Administration for the SENSUSTM, a pain therapy device for people who suffer diabetic neuropathy. A 510(k) is a "premarket notification" of a company's intent to market a medical product. The FDA then tests the product and provides feedback to the manufacturer. Once the FDA clears the product, its maker can introduce it to the US market.
SENSUS is a "transcutaneous electrical nerve stimulation" device that works by sending low-voltage currents to nerves through electrodes attached to the skin. In diabetic neuropathy, nerves become inflamed and damaged over time from high blood sugar levels. Studies have shown that many people afflicted with neuropathy enjoy relief from pain when affected nerves receive electric stimulation.
Up to 20 percent of people with diabetes suffer from diabetic neuropathy. If the condition is advanced, they can experience extreme pain and loss of mobility. Physicians usually treat the condition with drugs, which have varying degrees of effectiveness. NeuroMetrix says that eventual FDA approval of SENSUS will make available another mode of pain management.
Categories: Blood Glucose, Diabetes, Diabetes, Diabetic, Diabetic Complications, Drugs, FDA, Food, Mobility Loss, Nerve Care (Neuropathy), Nerve Pain, NeuroMetrix SENSUS, Pain, Type 1 Issues, US Food and Drug Administration
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.